GoodRx Holdings, Inc. (GDRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GoodRx Holdings, Inc. (GDRX) trades at $3.04 with AI Score 44/100 (Grade C). GoodRx Holdings, Inc. is a healthcare technology company that provides a price comparison platform for prescription drugs in the United States. Market cap: $1.06B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026GDRX stock analysis for 2026: Analysts have set a consensus price target of $2.88 for GoodRx Holdings, Inc., suggesting 5.4% downside from the current price of $3.04. The AI MoonshotScore is 44/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
GDRX: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →GoodRx Holdings, Inc. (GDRX) Healthcare & Pipeline Overview
GoodRx Holdings, Inc. is a leading healthcare technology firm specializing in prescription drug price comparison, empowering consumers to save money through negotiated discounts and a user-friendly platform, while addressing the rising costs of healthcare in the U.S.
What Is the Investment Thesis for GDRX?
GoodRx Holdings, Inc. presents a compelling growth thesis driven by several key factors. With a market capitalization of $1.06B and a P/E ratio of 43.2, the company operates in a high-margin environment, boasting a gross margin of 89.3%. The ongoing shift towards digital healthcare solutions and price transparency positions GoodRx favorably within the industry. The increasing demand for cost-effective healthcare options, particularly in the wake of rising prescription drug prices, is expected to drive user engagement and platform adoption. Furthermore, the company's expansion into telehealth services and partnerships with pharmaceutical manufacturers could enhance revenue streams and market presence. However, the company faces ongoing risks, including regulatory challenges and competition from other healthcare technology firms. Investors should closely monitor these dynamics as GoodRx continues to evolve.
Based on FMP financials and quantitative analysis
GDRX Key Highlights
- Market Cap of $1.06B reflects strong positioning in healthcare technology.
- P/E ratio of 43.2 indicates investor confidence in future growth.
- Gross margin of 89.3% highlights operational efficiency and profitability potential.
- Profit margin of 3.7% suggests room for improvement in cost management.
- Beta of 1.47 indicates higher volatility compared to the market, reflecting investor sentiment.
Who Are GDRX's Competitors?
GDRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CVS CVS Health Corporation | $102.14 | -2.47% | $130.32B | 74 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GDRX's Key Strengths?
- Strong market presence in prescription drug price comparison.
- High gross margin indicating operational efficiency.
- Diverse service offerings including telehealth and subscriptions.
What Are GDRX's Weaknesses?
- Relatively low profit margin compared to industry standards.
- Dependence on advertising revenue which may fluctuate.
- Limited international presence.
What Could Drive GDRX Stock Higher?
- Expansion of telehealth services to capture a growing market.
- Increasing user engagement driven by rising prescription drug prices.
- Strategic partnerships with pharmaceutical manufacturers to enhance service offerings.
What Are the Key Risks for GDRX?
- Financial-distress signal — its Altman Z-Score of 0.25 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 43.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory changes that could impact pricing strategies.
- Competition from established healthcare firms and new entrants.
- Fluctuations in advertising revenue affecting overall profitability.
What Are the Growth Opportunities for GDRX?
- Growth opportunity 1: GoodRx's expansion into telehealth services represents a significant growth driver. The telehealth market is projected to reach $459.8 billion by 2030, driven by increased consumer adoption and demand for convenient healthcare solutions. GoodRx's established user base and brand trust can facilitate rapid growth in this segment, enhancing overall revenue.
- Growth opportunity 2: The increasing focus on prescription drug price transparency presents an opportunity for GoodRx to capture a larger market share. As consumers become more aware of their medication costs, the demand for price comparison tools is expected to grow. This trend could lead to increased user engagement and higher transaction volumes on the platform.
- Growth opportunity 3: Partnerships with pharmaceutical manufacturers can enhance GoodRx's service offerings and create new revenue streams. By collaborating with drug manufacturers, GoodRx can provide exclusive discounts and access to promotional pricing, further attracting consumers to its platform and increasing its competitive advantage.
- Growth opportunity 4: Geographic expansion into underserved markets can drive user growth. By targeting areas with limited access to affordable medications, GoodRx can establish itself as a key player in these regions, potentially increasing its user base and transaction volume significantly.
- Growth opportunity 5: The rise of personalized medicine and targeted therapies can create demand for GoodRx's services as consumers seek cost-effective options for specialized medications. By positioning itself as a trusted resource for pricing information on these therapies, GoodRx can tap into a growing segment of the healthcare market.
What Opportunities Does GDRX Have?
- Expansion into telehealth services with high market potential.
- Growing demand for price transparency in healthcare.
- Partnerships with pharmaceutical manufacturers for exclusive offers.
What Threats Does GDRX Face?
- Regulatory challenges impacting pricing models.
- Intense competition from other healthcare technology firms.
- Potential changes in consumer behavior affecting platform usage.
What Are GDRX's Competitive Advantages?
- Established brand recognition and trust among consumers.
- User-friendly platform that simplifies price comparison.
- Strong partnerships with pharmacies and pharmaceutical companies.
- Proprietary data analytics capabilities for better service delivery.
What Does GDRX Do?
GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California. The company was founded with the mission of making prescription medications more affordable and accessible to consumers in the United States. Through its innovative price comparison platform, GoodRx enables users to compare prices for prescription drugs at local pharmacies, providing them with curated, geographically relevant pricing information. The platform allows consumers to access negotiated prices through GoodRx codes, which can be used to save money on their prescriptions. In addition to its core offerings, GoodRx has expanded its services to include telehealth solutions, subscription services, and partnerships with pharmaceutical manufacturers, enhancing its value proposition in the healthcare market. The company serves a diverse clientele, including pharmacy benefit managers who manage formularies and prescription transactions, thereby establishing pricing between consumers and pharmacies. GoodRx has positioned itself as a critical player in the healthcare information services industry, leveraging technology to disrupt traditional pharmacy practices and improve consumer access to affordable medications. As of now, GoodRx employs approximately 738 individuals, reflecting its growth and commitment to delivering innovative healthcare solutions.
What Products and Services Does GDRX Offer?
- Operate a price comparison platform for prescription drugs in the U.S.
- Provide consumers with tools to compare medication prices at local pharmacies.
- Offer negotiated prices through GoodRx codes for savings on prescriptions.
- Deliver telehealth services for convenient access to healthcare providers.
- Facilitate partnerships with pharmaceutical manufacturers for exclusive discounts.
- Serve pharmacy benefit managers to manage formularies and pricing.
How Does GDRX Make Money?
- Generate revenue through advertising partnerships with pharmacies and pharmaceutical companies.
- Earn fees from telehealth services provided to consumers.
- Offer subscription services that provide additional benefits to users.
- Leverage data analytics to enhance service offerings and improve user experience.
What Industry Does GDRX Operate In?
The healthcare information services industry is experiencing significant growth, driven by the increasing demand for transparency in prescription drug pricing and the rising costs of healthcare. The market is projected to expand as consumers seek cost-saving solutions and as technology continues to play a crucial role in healthcare delivery. GoodRx Holdings, Inc. is well-positioned within this landscape, leveraging its price comparison platform to meet the needs of cost-conscious consumers. The competitive landscape includes various players offering similar services, but GoodRx's established brand recognition and user-friendly platform provide a competitive edge.
Who Are GDRX's Key Customers?
- Individual consumers seeking affordable prescription medications.
- Pharmacy benefit managers looking to manage prescription pricing.
- Pharmacies aiming to attract more customers through competitive pricing.
- Pharmaceutical manufacturers interested in promoting their products.
How GoodRx Holdings, Inc. Is Valued
GoodRx Holdings, Inc. carries a market capitalization of $1.06B, placing it in the small-cap category. Relative to its peer group, GDRX's quantitative score of 44/100 is below the peer average of 68/100.
Company Profile
GoodRx Holdings, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Santa Monica, US. The company is led by CEO Wendy Barnes. GDRX has traded publicly since 2020.
ROE 3%Key Financial Metrics
Return on equity for GoodRx Holdings, Inc. stands at 3.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.0%, showing how much profit it generates from its asset base. GDRX trades at a trailing price-to-earnings ratio of 43.24, above the Healthcare sector average of ~23x. Its free cash flow yield is 14.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
GoodRx Holdings, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.25 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project GoodRx Holdings, Inc. revenue of about $775.9M for fiscal 2026, with EPS near $0.31. The estimate reflects 11 contributing analysts.
Net buyingInsider Activity
Over the past six months, GoodRx Holdings, Inc. insiders filed 28 SEC Form 4 transactions — 12 sales and 16 purchases. On net that is roughly 590K shares acquired (about $62K) — insiders putting money in tends to read as conviction.
GDRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- GoodRx has seen recent insider buying, suggesting confidence in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting the increasing demand for affordable healthcare solutions.
- The ongoing expansion of partnerships with pharmacies enhances its market position and accessibility for users.
- Recent marketing campaigns have resonated well, leading to higher engagement and brand recognition among consumers.
Bear Case
- Concerns over regulatory scrutiny in the healthcare sector may impact operational flexibility and growth.
- Community discussions reflect skepticism regarding the sustainability of user growth amidst increasing competition.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's profitability trajectory.
- Market perception has been clouded by broader economic challenges, which could affect consumer spending on healthcare services.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
GDRX Latest News
-
[Latest] Global Healthcare Discount Plan Market Size/Share Worth USD 48.37 Billion by 2035 at a 8.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Yahoo! Finance: GDRX News · Jun 25, 2026
-
2 Healthcare Stocks to Consider Right Now and 1 We Brush Off
Yahoo! Finance: GDRX News · Jun 25, 2026
-
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Yahoo! Finance: GDRX News · Jun 19, 2026
-
Q1 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
Yahoo! Finance: GDRX News · Jun 17, 2026
GDRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GDRX.
Price Targets
Consensus target: $2.88
GDRX MoonshotScore
What does this score mean?
The MoonshotScore rates GDRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
[Latest] Global Healthcare Discount Plan Market Size/Share Worth USD 48.37 Billion by 2035 at a 8.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
2 Healthcare Stocks to Consider Right Now and 1 We Brush Off
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Q1 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
Leadership: Wendy Barnes
CEO
Wendy Barnes has extensive experience in the healthcare technology sector, having held various leadership roles prior to joining GoodRx. She holds an MBA from a prestigious university and has a proven track record in driving growth and innovation within healthcare companies.
Track Record: Under Wendy's leadership, GoodRx has expanded its service offerings and increased user engagement significantly. She has been instrumental in forging partnerships that enhance the company's market position and drive revenue growth.
GoodRx Holdings, Inc. Healthcare Stock: Key Questions Answered
What does GoodRx Holdings, Inc. do?
GoodRx Holdings, Inc. operates a price comparison platform that allows consumers to find the best prices for prescription medications at local pharmacies. The platform provides access to negotiated prices through GoodRx codes, enabling users to save on their prescriptions. Additionally, GoodRx offers telehealth services and partnerships with pharmaceutical manufacturers, enhancing its value proposition in the healthcare market.
What do analysts say about GDRX stock?
Analysts generally view GoodRx Holdings, Inc. as a key player in the healthcare technology sector, particularly in prescription drug price transparency. Key valuation metrics include a P/E ratio of 43.2, indicating growth expectations. Analysts highlight the company's potential for revenue growth through telehealth services and partnerships, while also noting the competitive landscape and regulatory risks that could impact performance.
What are the main risks for GDRX?
GoodRx Holdings, Inc. faces several risks, including regulatory challenges that may affect its pricing models and operations. The company also contends with intense competition from other healthcare technology firms, which could impact market share. Additionally, fluctuations in advertising revenue could affect overall profitability, making it crucial for GoodRx to diversify its revenue streams and continue innovating.
What are the key factors to evaluate for GDRX?
GoodRx Holdings, Inc. (GDRX) holds an AI score of 44/100 (low). P/E: 43.2x vs the S&P 500's ~20-25x. Analysts target $2.88 (-5%). Not financial advice.
How frequently does GDRX data refresh on this page?
GDRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GDRX's recent stock price performance?
GoodRx Holdings, Inc. (GDRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in prescription drug price comparison. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GDRX overvalued or undervalued right now?
GoodRx Holdings, Inc. (GDRX) trades at 43.2x earnings. Analysts target $2.88 (-5%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GDRX?
Before investing in GoodRx Holdings, Inc. (GDRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on current financial data and market conditions as of May 2026.